CLINICAL_TRIALS
trial_result
· 2014-08-05
Clinical Trial Update: Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study [Phase 2]
Summary
A Phase 2 dose-ranging study evaluated desoximetasone topical spray at 0.05% and 0.25% for psoriasis, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2014-08-05